Abpro Holdings, Inc.

Abpro Holdings, Inc., trading under the ticker ABP, is a clinical-stage biopharmaceutical company that reached public markets through a SPAC transaction and operates in the biotechnology and drug development sector. The company filed its most recent Form 10-Q on November 26, 2024, under accession number 0001213900-24-102370, reflecting its status as a reporting company with the Securities and Exchange Commission. Abpro is focused on antibody-based therapeutic development, positioning itself within the broader biopharmaceutical industry. Investors and analysts tracking SPAC-derived biotech issuers can find comprehensive filing data, deal history, and performance metrics for ABP and hundreds of comparable companies by signing up for full access at SpacDesk.